Predictive model for preoperative determination of microscopic residual disease at the time of primary cytoreduction in patients with advanced-stage epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) 182 analysis

Horowitz, Neil

60 - Scientific Plenary
Predictive model for preoperative determination of microscopic residual disease at the time of primary cytoreduction in patients with advanced-stage epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) 182 analysis

Sunday, March 23, 2014: 11:31 AM

Ballroom B/C (Tampa Convention Center)

N. S. Horowitz¹, A. Miller², B. J. Rungruang³, T. C. Krivak⁴, S. D. Richard⁵, C. A. Hamilton⁶, N. Rodriguez⁷, M. A. Bookman⁸ and G. L. Maxwell⁹
¹Harvard University, Boston, MA, ²Gynecologic Oncology Group, Buffalo, NY, ³Georgia Reagents University, Evans, GA, ⁴Western Pennsylvania Hospital, Pittsburgh, PA, ⁵Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA, ⁶Walter Reed National Military Medical Center, Bethesda, MD, ⁷Loma Linda University Medical Center, Loma Linda, CA, ⁸University of Arizona Cancer Center, Tucson, AZ, ⁹Inova Fairfax Hospital, Falls Church, VA

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

60 - Scientific Plenary
Predictive model for preoperative determination of microscopic residual disease at the time of primary cytoreduction in patients with advanced-stage epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) 182 analysis

60 - Scientific Plenary Predictive model for preoperative determination of microscopic residual disease at the time of primary cytoreduction in patients with advanced-stage epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) 182 analysis

60 - Scientific Plenary
Predictive model for preoperative determination of microscopic residual disease at the time of primary cytoreduction in patients with advanced-stage epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) 182 analysis